NIH ramps investments in women's health research
Key Questions
What recent funding commitment has the NIH made to women's health research?
The NIH has signaled roughly USD 500 million in renewed, directed funding for women's health research. This includes at least one early award to Dare Bioscience, confirming concrete activity.
What types of funding opportunities are expected from the NIH?
Near-term RFAs, SBIR/STTR windows, and translational funding are anticipated, mapping directly to diagnostics, implementation research, and clinical FemTech. Teams should begin grant-stacking and PO mapping now.
How has venture capital investment in women's health startups trended recently?
In 2024, women's health startups raised $2.6 billion in venture capital, a 55% increase from the prior year. This reflects growing investment interest in the sector.
What is BASE4 Biosciences developing with its recent funding?
BASE4 Biosciences raised $1 million in pre-seed funding to build a sex-specific biological atlas from a single blood test using a multi-omic platform. This aims to advance personalized women's health insights.
What are the key signals defining the future of women's health?
Five signals from Q1 2026 highlight trends including investments like BASE4 Biosciences and ScreenPoint Medical. These point to increased focus on sex-specific diagnostics and biological mapping.
NIH signals roughly USD 500M in renewed, directed women's‑health funding; at least one early award to Dare Bioscience confirms concrete activity. Expect near‑term RFAs, SBIR/STTR windows and translational funding that map directly to diagnostics, implementation research and clinical FemTech; teams should begin grant‑stacking and PO mapping now.